Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) Cost of Revenue: 2016-2024

Historic Cost of Revenue for Organogenesis Holdings (ORGO) over the last 9 years, with Dec 2024 value amounting to $115.7 million.

  • Organogenesis Holdings' Cost of Revenue rose 10.65% to $53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.7 million, marking a year-over-year decrease of 43.27%. This contributed to the annual value of $115.7 million for FY2024, which is 8.70% up from last year.
  • According to the latest figures from FY2024, Organogenesis Holdings' Cost of Revenue is $115.7 million, which was up 8.70% from $106.5 million recorded in FY2023.
  • In the past 5 years, Organogenesis Holdings' Cost of Revenue registered a high of $115.7 million during FY2024, and its lowest value of $87.3 million during FY2020.
  • Its 3-year average for Cost of Revenue is $109.1 million, with a median of $106.5 million in 2023.
  • Its Cost of Revenue has fluctuated over the past 5 years, first spiked by 30.78% in 2021, then fell by 8.04% in 2022.
  • Organogenesis Holdings' Cost of Revenue (Yearly) stood at $87.3 million in 2020, then soared by 30.78% to $114.2 million in 2021, then declined by 8.04% to $105.0 million in 2022, then increased by 1.39% to $106.5 million in 2023, then increased by 8.70% to $115.7 million in 2024.